Navigation Links
ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
Date:11/13/2007

LEUVEN, Belgium, November 14 /PRNewswire/ --

- Key Research Findings Published in the Leading Medical Journal `Blood' Validate Drug Target

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, announces today that it will progress with the development of its novel anti-VPAC(1) antibody for the treatment of thrombocytopenia, including chemotherapy-induced thrombocytopenia.

Thrombocytopenia, which is the reduced number of platelets in blood, is a common severe side effect of chemotherapy and increases the risk of bleeding and severity of haemorrhage, therefore causing the delay or even discontinuation of treatment in cancer patients. There is a high medical need to find a therapeutic that could reduce thrombocytopenia by accelerating platelet production. Blood transfusion, the current standard of care for this condition, offers only a temporary solution for these patients and is associated with significant cost and risk.

Researchers at the University of Leuven and ThromboGenics have developed a novel therapeutic approach, showing that the inhibition of VPAC could stimulate the production of platelets. ThromboGenics has now identified and selected a lead antibody against VPAC to enter preclinical development. VPAC is a receptor present at the surface of bone marrow cells called megakaryocytes, which, when mature, produce platelets. Research published yesterday in Blood describes how the inhibition of VPAC could promote megakaryocyte differentiation. Blood is the official journal of the American Society of Hematology (ASH).

Prof. Desire Collen, CEO and Chairman of ThromboGenics, commented: "Thrombocytopenia is a severe complication of cancer patients receiving chemotherapy, and for which there is little therapeutic alternative. I am very pleased to advance our thrombocytopenia programme to preclinical development, which I hope will confirm the potential of our approach published in Blood. Thi
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. PA Department of Public Welfare Begins Outreach to Medical Assistance Consumers Following Burglary at State Office Building
3. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
4. Most comprehensive study of mercury in dental fillings begins
5. Eye Safety Begins at Home
6. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
7. OmniGuide Begins European Commercialization
8. From Microscope to Stethoscope: the MUHCs distinguished public lecture series begins a second seaso
9. From microscope to stethoscope: The MUHCs public lecture series begins its 2nd season tomorrow
10. North Shore-LIJ Health System Begins Online Posting of Hospital Infection Rates, Other Performance Information
11. Healthy Weight Loss Begins With What You Permit to Enter Your Mind, More So Than Even Your Mouth!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
(Date:4/17/2014)... and their partners have found that their proprietary microbicide ... of multiple sexually transmitted infections (STIs) in both the ... 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded study ... effective against multiple strains of HIV, and has a ... viruses of at least eight hours prior to exposure. ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... of the University of Pennsylvania reported today that students ... activity are less likely to smoke than their classmates. ... participation extends at least three years beyond graduation. The ... the same level of protection from school sports as ...
... SATELLITE FEED: ... 6:30 PM - 6:45 PM ET ... C-Band ... Downlink Freq: 3980 Horizontal NEWS: Football Legend John Madden ...
... Created by Hospitals from Around the Country Appeal to the ... Contest to Win a Free MRI, MALVERN, Pa., Dec. 6 ... community, but can,t seem to find the time,now,s your chance to ... click of your mouse! The video posting period in Siemens first-ever,"Win ...
... SAN DIEGO, Dec. 6 Neurocrine Biosciences,Inc. (Nasdaq: ... has closed its sale,and leaseback agreement with Veralliance ... by Neurocrine for the properties was,$109 million. Concurrently ... its corporate headquarters for a 12 year term, ...
... on Christmas ... harmony, CINCINNATI, Dec. 6 As they,re searching the ... toys they,think are safe, now parents have a new worry: ... because the unsafe toy they wanted,isn,t under the tree., ...
... Dec. 6 Dr. Belinda Tsao-Nivaggioli,Chief Executive Officer ... http://www.avicenagroup.com ) will be featured in an exclusive ... at 5 p.m. EST. The interview,will be posted ... on December 10., The interview will cover ...
Cached Medicine News:Health News:Participation in organized high school activities lowers risk of smoking 3 years after graduation 2Health News:Participation in organized high school activities lowers risk of smoking 3 years after graduation 3Health News:The Polls are Open! America Votes to Decide Which Hospital is the Most Deserving of Siemens' Newest MRI Technology 2Health News:The Polls are Open! America Votes to Decide Which Hospital is the Most Deserving of Siemens' Newest MRI Technology 3Health News:Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets 2Health News:Concern Over Toy Safety and Disappointed Kids Impacts Holidays for Parents 2Health News:Concern Over Toy Safety and Disappointed Kids Impacts Holidays for Parents 3Health News:WallSt.net Announces Upcoming Interview With CEO of Avicena Group 2
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
(Date:1/14/2014)... PORT WASHINGTON, New York , January 14, ... the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, ... sales growth for the fourth straight year.   ... of exposure for pharmacy technicians, pharmacists, nurses and ...
(Date:1/14/2014)... FRANCISCO , Jan. 14, 2014 Spark Therapeutics , ... for its most advanced clinical program, a Phase 3 study for ... gene. Spark,s CEO, Jeffrey D. Marrazzo , is presenting this ... Healthcare Conference in San Francisco . Marrazzo said ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... officials in FDA,s Office of New Drugs (OND), the ... a cardiovascular outcomes trial (CVOT) for Contrave® that would ... 2011. Orexigen believes that these design requirements are reasonable ...
... CLEVELAND, Sept. 20, 2011 Dr. Melisa Estes, who is ... suffer from chronic knee pain. She recently began incorporating a ... nerve stimulation, also known as TENS, sends electrical stimulation to ... signals from reaching the brain, and that reduces pain. ...
Cached Medicine Technology:Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 2Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 3Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 4Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 5Knee Pain Control - No Drugs - Doctor Used 2
The Panorama Central Station includes bi-directional communication with Datascope bedside monitors, optional 72 hours of disclosure and a touch screen user interface....
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
Developed in a Microsoft Windows environment, MedInformatix provides physician practices a Computerized Patient Record (CPR) with a Practice Management System (PMS) that is both integrated and design...
Medicine Products: